TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7766744
Drug: Effervescent ranitidine
Normalized name: ranitidine Effervescent Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Effervescent ranitidine (300 mg)
Study: 7766744
Drug: Regular ranitidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular ranitidine (300 mg)
Study: 7766744
Drug: Effervescent cimetidine
Normalized name: cimetidine Effervescent Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Effervescent cimetidine (800 mg)
Study: 7766744
Drug: Regular cimetidine
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Regular cimetidine (800 mg)
Study: 12480822
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of [3H]L-arginine (300 nCi/min)
Study: 16139123
Drug: Losartan with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan with aspirin (n = 1,004)
Study: 16139123
Drug: Atenolol with
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atenolol with aspirin (n = 966)
Study: 16139123
Drug: Losartan with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan with aspirin
Study: 16139123
Drug: Atenolol with
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atenolol with aspirin
Study: 7844608
Drug: HFX RT
Approvals — FDA: no, EMA: no, PMDA: no
Description: HFX RT with 1.2 Gy twice daily to a total dose of 64.8 Gy (group I)
Study: 7844608
Drug: HFX RT
Approvals — FDA: no, EMA: no, PMDA: no
Description: HFX RT with CHT (100 mg of carboplatin on days 1 and 2 and 100 mg of etoposide on days 1 to 3 of each week during RT course) (group II)
Study: 7844608
Drug: HFX RT
Approvals — FDA: no, EMA: no, PMDA: no
Description: HFX RT with CHT (200 mg of carboplatin on days 1 and 2 and 100 mg of etoposide on days 1 to 5 of the first, third, and fifth weeks of RT course) (group III)
Study: 2189903
Drug: Nilvadipine 6
Normalized name: nilvadipine
DrugBank: Nilvadipine (DB06712)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nilvadipine 6 mg tid
Study: 2189903
Drug: Nilvadipine 8
Normalized name: nilvadipine 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nilvadipine 8 mg tid
Study: 2189903
Drug: Nilvadipine 10
Normalized name: nilvadipine
DrugBank: Nilvadipine (DB06712)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nilvadipine 10 mg tid
Study: 27529732
Drug: Orthodontic camouflage
Normalized name: monofluorophosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orthodontic camouflage treatment (OCT)
Study: 17016954
Drug: Fortified dietary
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fortified dietary supplement (25 g per school day for children; two 25-g sachets per day for pregnant women)
Study: 17016954
Drug: Fortified dietary
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fortified dietary supplement
Study: 17016954
Drug: Nonfortified supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonfortified supplement
Study: 8723804
Drug: Intratracheal instillation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intratracheal instillation of large doses of bovine and porcine lung-derived surfactant preparations
Study: 1677276
Drug: Electromyographic feedback
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electromyographic feedback training with contingent tone based on oral-lingual movements above a yoked threshold.
Study: 6129933
Drug: Almitrine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almitrine (1 mg/kg intravenously)
Study: 22552048
Drug: Docetaxel-based therapy
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel-based therapy (DP) following ketoconazole (KC)
Study: 22552048
Drug: Docetaxel-based therapy
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel-based therapy (DP) in KC-naive patients
Study: 21718804
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil supplementation (650 mg daily, containing 250-280 mg DHA and at least 60 mg EPA)
Study: 21718804
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil supplementation (650 mg daily)
Study: 15330959
Drug: OTFC (normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: OTFC (normal dose = 10-15 microg x kg(‐1) or low dose = 100 microg)
Study: 15330959
Drug: ondansetron (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: ondansetron (0.1 mg x kg(‐1) to 4 mg)
Study: 2906898
Drug: Tienoxolol 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tienoxolol 150 mg
Study: 2906898
Drug: Tienoxolol 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tienoxolol 300 mg
Study: 21554128
Drug: Saw palmetto
Normalized name: Saw palmetto
DrugBank: Saw palmetto (DB14360)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saw palmetto given at escalating doses over an 18-month period
Study: 18315429
Drug: Subantimicrobial dose
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subantimicrobial dose doxycycline (SDD) 20 mg, twice a day for 3 months plus scaling and root planing
Study: 18315429
Drug: Placebo capsules,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules, twice a day for 3 months plus scaling and root planing
Study: 16513078
Drug: Pyrimethamine-sulfadoxine (PS)
Normalized name: pyrimethamine / sulfadoxine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyrimethamine-sulfadoxine (PS) treatment
Study: 11790519
Drug: Tricyclic antidepressant
Normalized name: Tricyclic antidepressant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tricyclic antidepressant (TCA)
Study: 11790519
Drug: Monoamine oxidase
Normalized name: Monoamine oxidase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monoamine oxidase inhibitor
Study: 11790519
Drug: Alternative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternative treatment for nonresponders
Study: 8789577
Drug: Ubiquinone supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ubiquinone supplementation (120 mg.day‐1 for 6 weeks)
Study: 30203754
Drug: Sequential therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential therapy with azithromycin
Study: 24843650
Drug: Exenatide once
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exenatide once weekly (2 mg)
Study: 19781120
Drug: Beta-glucan soup
Normalized name: Beta glucan
DrugBank: Yeast beta-D-glucan (DB19271)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-glucan soup (3.5 g/d) for 8 weeks
Study: 17268215
Drug: valsartan/hydrochlorothiazide 320/25
Approvals — FDA: no, EMA: no, PMDA: no
Description: valsartan/hydrochlorothiazide 320/25 mg
Study: 17268215
Drug: valsartan/hydrochlorothiazide (combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: valsartan/hydrochlorothiazide (combination therapy)
Study: 17268215
Drug: valsartan (incremental
Approvals — FDA: no, EMA: no, PMDA: no
Description: valsartan (incremental doses)
Study: 7477167
Drug: Ritonavir (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritonavir (600 mg every 12 hours)
Study: 7477167
Drug: Ritonavir (higher-dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritonavir (higher-dosage groups)
Study: 1979634
Drug: reserpine-containing combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: reserpine-containing combination
Study: 7013060
Drug: Methylprednisolone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (30 mg per kg body weight)
Study: 31789486
Drug: Drug-coated balloon
Normalized name: CATHETER,BALLOON
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-coated balloon (DCB) treatment for early DES-ISR
Study: 31789486
Drug: Drug-coated balloon
Normalized name: CATHETER,BALLOON
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-coated balloon (DCB) treatment for late DES-ISR
Study: 31163212
Drug: SSRIs (escitalopram
Approvals — FDA: no, EMA: no, PMDA: no
Description: SSRIs (escitalopram or sertraline) for 12 weeks
Study: 30053031
Drug: Hyperosmolar saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperosmolar saline (1500 mOsm/L)
Study: 30053031
Drug: Isoosmolar saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoosmolar saline (300 mOsm/L)
Study: 19576311
Drug: Optimal medical
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal medical therapy (OMT) + percutaneous coronary intervention (PCI)
Study: 24440015
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of anatomic and ischemic burden
Study: 10071526
Drug: Albuterol aerosol
Normalized name: Albuterol Inhalation Aerosol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol aerosol (180 micrograms)
Study: 6795049
Drug: Intralipid plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralipid plus glucose infusion
Study: 26935876
Drug: Vonoprazan 20
Normalized name: vonoprazan 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vonoprazan 20 mg as part of first-line triple therapy (with amoxicillin 750 mg and clarithromycin 200 or 400 mg)
Study: 26935876
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg as part of first-line triple therapy (with amoxicillin 750 mg and clarithromycin 200 or 400 mg)
Study: 26935876
Drug: Second-line vonoprazan-based
Normalized name: vonoprazan
DrugBank: Vonoprazan (DB11739)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Second-line vonoprazan-based triple therapy (with amoxicillin 750 mg and metronidazole 250 mg)
Study: 24662210
Drug: Matched treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched treatment (trunk stabilization exercise)
Study: 24662210
Drug: Unmatched treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unmatched treatment (Movement System Impairment‐directed exercises)
Study: 22257523
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with trastuzumab (ECH-TH group)
Study: 22257523
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with lapatinib (ECL-TL group)
Study: 18829075
Drug: Single apical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single apical injection of 5 mL lidocaine
Study: 18829075
Drug: Bilateral basal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral basal injection of 2 injections of 5 mL lidocaine
Study: 15040542
Drug: LPV/ritonavir (LPV/r)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LPV/ritonavir (LPV/r) in combination with other antiretroviral agents
Study: 9730852
Drug: Subcutaneous GLP-1
Normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous GLP-1 (3 times a day before meals)
Study: 7914733
Drug: L-carnitine (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine (6 g/day)
Study: 29587655
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg levobupivacaine combined with fentanyl (GL6)
Study: 29587655
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg levobupivacaine combined with fentanyl (GL8)
Study: 24766732
Drug: Axitinib at
Normalized name: Axitinib
DrugBank: Axitinib (DB06626)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Axitinib at a starting dose of 5-mg twice daily continuously plus pemetrexed 500 mg/m² and cisplatin 75 mg/m² on day 1 of up to six 21-day cycles (arm I)
Study: 20003124
Drug: Bolus dose
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus dose of propofol 1.8 mg/kg at a rate of 1200 ml/h
Study: 20003124
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of propofol 12 mg/kg/h
Study: 16313113
Drug: SS syrup
Normalized name: ANATUSS SYRUP
Approvals — FDA: no, EMA: no, PMDA: no
Description: SS syrup
Study: 8893680
Drug: Low-dose recombinant
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose recombinant FSH (40 cycles)
Study: 8893680
Drug: Low-dose hMG
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose hMG (26 cycles)
Study: 8295364
Drug: PhXA41 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: PhXA41 25 micrograms/ml
Study: 8295364
Drug: PhXA41 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: PhXA41 50 micrograms/ml
Study: 8295364
Drug: PhXA41 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: PhXA41 100 micrograms/ml
Study: 3631982
Drug: Fluocinolone acetonide
Normalized name: Fluocinolone Acetonide
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluocinolone acetonide cream (twice-daily applications)
Study: 3631982
Drug: Erythemogenic ultraviolet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythemogenic ultraviolet B treatment
Study: 31868907
Drug: Molecular panel-guided
Normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Molecular panel-guided treatment for selected mutations
Study: 28125168
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg daily oral Prednisone for one month
Study: 28125168
Drug: 12.5 mg
Normalized name: rutin 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5 mg daily oral Prednisone for one month
Study: 28125168
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg daily oral Prednisone for one month
Study: 19336639
Drug: Sliding‐scale regular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sliding‐scale regular insulin (SSRI) alone (n = 25)
Study: 19336639
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine (n = 25)
Study: 8476402
Drug: Cognitive-behavioral group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral group treatment
Study: 15000515
Drug: Interactional group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interactional group treatment
Study: 15000515
Drug: Psychosocial and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychosocial and biological indicators
Study: 1850686
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of [3H]noradrenaline
Study: 6645778
Drug: Electric convulsive
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Electric convulsive therapy (ECT)
Study: 25828280
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline 0.1 ml/kg (Control)
Study: 23312881
Drug: Aflibercept 4
Normalized name: aflibercept 40 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aflibercept 4 mg/kg with irinotecan-LV5FU2 every 2 weeks
Study: 21166834
Drug: Neurochemical intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neurochemical intervention involving L-theanine and 5-hydroxytryptophan
Study: 15114122
Drug: Injection microdome
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Injection microdome positioned in the parasternal area
Study: 15114122
Drug: Injection microdome
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Injection microdome positioned in the lower lateral thoracic area
Study: 3153025
Drug: Plasma infusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma infusions (plasma group, n = 39)
Study: 30649925
Drug: Two insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two insulin pumps
Study: 30649925
Drug: All system
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All system configurations (using CGMs and insulin pumps)
Study: 26525477
Drug: Furasol sore
Normalized name: Sucrets Sore Throat
DrugBank: Dyclonine (DB00645)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Furasol sore throat gargle solution
Study: 29631615
Drug: Antibacterial therapy
Normalized name: Dermoplast Antibacterial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibacterial therapy
Study: 16481919
Drug: iomeprol 400
Normalized name: Iomeprol 400 MG/1 ML Injection Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: iomeprol 400 (400 mg iodine/mL)
Study: 16481919
Drug: iopromide 370
Normalized name: IOPROMIDE 370mgI/ml INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: iopromide 370 (370 mg iodine/mL)
Study: 8261677
Drug: Protein intake
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein intake (g/kg/day)
Study: 8261677
Drug: Difference between
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Difference between protein-N intake and urea-N excretion
Study: 8261677
Drug: Correlation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Correlation of protein intake and urea-N excretion
Study: 3513667
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate (60 mg/kg)
Study: 20390593
Drug: Saccharide supplementation
Normalized name: Saccharide isomerate
DrugBank: Saccharide isomerate (DB11232)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saccharide supplementation (3.6 g per day, taken as a teaspoon twice daily for 12 weeks)
Study: 16134993
Drug: Fel d
Normalized name: Anti-cat allergen fel d 1 monoclonal anitbody regn-1908
DrugBank: Freneslerbart (DB19080)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fel d 1 peptides (approximately 300 mug in increasing, divided doses)
Study: 12218725
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogen (CEE, 0.625 mg daily) for 3 months, followed by CEE combined with low-dose medroxyprogesterone acetate (MPA, 2.5 mg daily) for an additional 3 months
Study: 10099941
Drug: Gaio (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gaio (200 g daily)
Study: 3126636
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg nitroglycerin (NTG) patch
Study: 23257248
Drug: Degarelix (240/80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Degarelix (240/80 mg monthly for 12 weeks)
Study: 23257248
Drug: Goserelin (3.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goserelin (3.6 mg monthly for 12 weeks) plus Bicalutamide (50 mg for 17 days initially)
Study: 21288121
Drug: Atomoxetine (ATX)
DrugBank: Atomoxetine (DB00289)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atomoxetine (ATX) dosed twice daily (BID)
Study: 21288121
Drug: Atomoxetine (ATX)
DrugBank: Atomoxetine (DB00289)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atomoxetine (ATX) dosed once daily (QD)
Study: 17941029
Drug: Neoadjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant therapy followed by prostatectomy
Study: 15088884
Drug: Low-dose flurbiprofen
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose flurbiprofen (LDF) alone, 50 mg q.d.
Study: 15088884
Drug: Subantimicrobial dose
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subantimicrobial dose doxycycline (SDD) alone, 20 mg b.i.d.
Study: 15088884
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of SDD plus LDF
Study: 11235927
Drug: Melatonin (5.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (5.4 mg mean stable dose)
Study: 10193290
Drug: Neostigmine 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine 2.0 mg and glycopyrrolate 0.4 mg
Study: 8091148
Drug: Continuous oral
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous oral pamidronate (APD), 1000 mg/day
Study: 1769820
Drug: Metoprolol 200
Normalized name: metoprolol 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol 200 mg daily
Study: 26980346
Drug: Warm temperature
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warm temperature (31°C) during oral glucose tolerance tests (OGTTs)
Study: 25765705
Drug: RM1 (≥3
Approvals — FDA: no, EMA: no, PMDA: no
Description: RM1 (≥3 days and/or nights of cough, wheeze, and/or medicine use) documented by parental diaries at 12 months corrected age
Study: 25765705
Drug: RM2 (≥4
Approvals — FDA: no, EMA: no, PMDA: no
Description: RM2 (≥4 days and/or nights of cough, wheeze, and/or respiratory medicine use) documented by parental diaries at 12 months corrected age
Study: 16600508
Drug: Oxycodone (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone (15 mg)
Study: 31391001
Drug: Control (0.9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (0.9% saline infusion)
Study: 12208482
Drug: Diet plus
Normalized name: Glucomannan/Grapefruit Extract/Pyridoxine Oral Tablet [GRAPEFRUIT DIET PLUS]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet plus pravastatin (40 mg/day)
Study: 10596735
Drug: Bupropion SR
Normalized name: Bupropion Hydrochloride 100 MG Oral Tablet, Extended Release, 12 HR [BUPROPION SR]
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupropion SR (150-400 mg/day)
Study: 10596735
Drug: Bupropion SR
Normalized name: Bupropion Hydrochloride 100 MG Oral Tablet, Extended Release, 12 HR [BUPROPION SR]
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupropion SR and Sertraline
Study: 19434360
Drug: 20 mg/day
Normalized name: futibatinib 20 mg/day (4 mg x 5) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/day omeprazole
Study: 6134979
Drug: 60 mg/day
Normalized name: cabozantinib s-malate 60 mg/day (20 mg x 3/day) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg/day omeprazole
Study: 27184789
Drug: Inpatient psychodynamic
Normalized name: Impatiens irvingii whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inpatient psychodynamic treatment
Study: 30986750
Drug: Statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin therapy at discharge
Study: 24576541
Drug: No statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: No statin therapy at discharge